Legislator Case Law & Legislation
812.212.21 VAMOMÉDOM CH

Ordinance of 21 September 2018 on Medicinal Products (OMed) (VAM)

94 Articles / Provisions · Switzerland · Federal Legislation (SR / Fedlex)
Open official source Machine-readable Markdown (.md)

Table of Provisions (94)

Statutory Text (94 Articles)

OMéd; Chapitre 1 Objet et champ d’application

This ordinance governs: a. the authorization for the marketing of ready-to-use medicinal products; b. the authorization of processes; c. the criteria for classification into dispensing categories; d. the restrictions on distribution; e. the authorization of mail-order sales of medicinal products; f. market surveillance and vigilance; g. the provision of information to the public; h. the list of dosage recommendations for the use of medicinal products in pediatrics; i. the publication of the results of clinical trials.

It also applies, by analogy, to standardized transplants as defined in Art. 2, para. 1, let. c, of the Ordinance of 16 March 2007 on Transplantation.

Art. 31 does not apply to standardized transplants as defined in Art. 2, para. 1, let. c, ch. 2, of the Ordinance of 16 March 2007 on Transplantation.

The definitions in Art. 2 of the Ordinance of 14 November 2018 on Authorizations in the Field of Medicinal Products (OAMed) are applicable.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The marketing authorization for ready-to-use medicinal products is governed by Art. 9 of the Therapeutic Products Act (TPA).

Authorization is required in all cases

a. for ready-to-use medicinal products that contain genetically modified organisms (GMOs);

b. for standardized transplants as defined in Art. 2, para. 1, letter c, of the Ordinance of 16 March 2007 on Transplantation.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The application for marketing authorization, as well as the required data and documents referred to in Arts. 11 and 14a of the Therapeutic Products Act (TPA), must be submitted to the Swiss Agency for Therapeutic Products (Swissmedic).

The application for marketing authorization of a medicinal product whose development is based on the use of genetic resources or traditional knowledge associated with those resources must also include the registration number pursuant to Art. 4, para. 3, or Art. 8, para. 5, of the Nagoya Ordinance of 11 December 2015.

Swissmedic will not consider incomplete or insufficient applications.

It may grant a period of up to 60 days to remedy the deficiencies.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

A risk management plan must be attached to: a. applications for marketing authorization of a human medicinal product containing at least one new active substance, according to the procedure specified in Art. 11 of the Therapeutic Products Act (ordinary procedure); b. applications for marketing authorization of an important medicinal product for treating rare diseases (orphan drug) containing at least one new active substance; c. applications for marketing authorization of a new indication for a medicinal product referred to in let. a or b that is already authorized.

It includes a risk assessment and a pharmacovigilance plan.

The pharmacovigilance plan outlines how the risks related to the use of the medicinal product are systematically cataloged and identified, as well as the planned prevention measures (Art. 11, para. 2, let. a, subpara. 5, of the Therapeutic Products Act).

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The pediatric investigation plan referred to in Art. 54a of the Therapeutic Products Act (TPA) must include a research and development program ensuring that the necessary data to determine the conditions under which the relevant medicinal product can be authorized for the treatment of the pediatric population will be developed.

A pediatric investigation plan must be attached to: a. applications for marketing authorization of a medicinal product containing at least one new active substance, under the regular procedure; b. applications for marketing authorization of a significant medicinal product for rare diseases (orphan drug) containing at least one new active substance; c. applications for marketing authorization for a new indication, a new pharmaceutical form, or a new route of administration for a medicinal product referred to in let. a or b that is already authorized.

This obligation is also fulfilled if the applicant submits the pediatric investigation plan most recently approved by a country designated by Swissmedic as having equivalent medicinal product oversight. The applicant shall promptly inform Swissmedic of compliance with all requirements set out in the investigation plan approved abroad.

Upon request or ex officio, Swissmedic may grant a partial or total waiver of the obligation to develop a pediatric investigation plan, particularly if: a. there is reason to believe that the medicinal product is likely to be ineffective in the pediatric population or its use is questionable for safety reasons; b. the medicinal product is intended for the treatment of a disease that occurs only in adults; c. the medicinal product does not appear to offer significant therapeutic benefits over existing treatments for pediatric patients.

Upon request or ex officio, it may authorize studies or other measures of the pediatric investigation plan to be initiated or completed at a later date, particularly: a. when it is appropriate to conduct studies on adults before initiating studies on the pediatric population; b. when studies on the pediatric population take longer than studies on adults.

Before the submission of a marketing authorization application, it may, upon request: a. approve a pediatric investigation plan; b. grant a waiver in accordance with para. 4, or c. authorize a deferral in accordance with para. 5.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The application for marketing authorization of a medicinal product containing GMOs must fulfill, in addition to the requirements under the TPA, the requirements of Art. 28 of the Ordinance of September 10, 2008, on the Deliberate Release into the Environment.

The competent authority directs and coordinates the marketing authorization procedure while taking into account the ordinance on the deliberate release into the environment.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The applicant may submit to Swissmedic a request for a fast track procedure for the marketing authorization of a medicinal product for human use or for a modification thereof if the following conditions are met: a. it concerns the promising prevention or treatment of a serious, disabling, or life-threatening disease; b. there is no possibility of treatment with authorized medicinal products or if the only existing treatment options are unsatisfactory; c. the use of the new medicinal product promises a high therapeutic benefit.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Before making its decision on the marketing authorization, Swissmedic communicates to the applicant the result of its review if it intends not to fully grant the application.

During the authorization process, it may request the applicant to clarify questions and, if necessary, to submit additional documents by setting an appropriate deadline for this purpose.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic grants the authorization if the medicinal product meets the requirements of therapeutic products legislation and, in the case of medicinal products containing GMOs, the conditions of the Ordinance of 10 September 2008 on the Release into the Environment.

Swissmedic only grants marketing authorization for a medicinal product whose development relies on the use of genetic resources or traditional knowledge associated with them if it is proven that the notification obligation under Art. 4 or 8 of the Nagoya Ordinance of 11 December 2015 is fulfilled.

For veterinary medicinal products for livestock animals, Swissmedic grants authorization only in cases where these products are such that the food obtained does not pose risks to human health.

It rejects the authorization request when the conditions are not met or when the name of the medicinal product or the presentation of its container or packaging material is contrary to public order and good morals, or is likely to mislead or cause confusion.

Upon request, it specifies in the authorization decision that the information on the medicinal product reproduces the results of relevant studies carried out in accordance with the pediatric investigation plan approved under Art. 54 a TPA.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The authorization is transferable.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

If a medicinal product is not brought to market within the year following the grant of authorization, the authorization holder must notify Swissmedic within 30 days after the end of said year.

If a medicinal product is no longer distributed or if its distribution is interrupted for more than one year, the authorization holder must notify Swissmedic. Notification must be made at least two months in advance, unless the discontinuation or interruption of distribution is due to circumstances that could not have been foreseen in time.

If a medicinal product authorized for pediatric use benefits from protection under Art. 11b, para. 3 or 4, TPRA or under Art. 140n or 140t of the Patent Act of 25 June 1954 and is no longer distributed, the authorization holder must notify Swissmedic. Notification must be made at least three months in advance unless the discontinuation of distribution results from circumstances that could not have been foreseen in time.

If a medicinal product mentioned in para. 1 is subsequently brought to market or its distribution resumes after an interruption, the authorization holder must notify Swissmedic within 30 days.

Swissmedic publishes notifications referred to in paras. 2 to 4. Concerning a discontinuation of distribution under para. 3, it specifies that the documentation related to the authorization for pediatric use can be obtained free of charge from the authorization holder.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The application for the renewal of the authorization must be submitted with the required documents at least six months before the expiration date.

Swissmedic may set a different submission deadline in the authorization decision, particularly for medicinal products under additional monitoring.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic revokes or suspends the marketing authorization when the conditions set forth in the Therapeutic Products Act (LPTh) are no longer fulfilled.

It revokes the marketing authorization when a medicinal product is no longer distributed.

The marketing authorization for medicinal products that have been authorized solely to address an emergency situation or are intended exclusively for export is not revoked upon the expiration of the deadlines set in Art. 16a, para. 1, LPTh.

The period referred to in Art. 16a, para. 1, lit. a, LPTh begins on the day the marketing authorization is granted. If a patent hinders the market launch, the period starts only upon the expiration of the patent.

The period referred to in Art. 16a, para. 1, lit. b, LPTh begins on the day the marketing authorization holder delivers the last package of the last batch to the wholesaler.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic re-examines medicinal products, pursuant to Art. 16 c LPTh, individually or by groups. In doing so, it particularly considers the following criteria: a. the scope of application of the medicinal product; b. the risks associated with the medicinal product; c. the development of technical and scientific knowledge. It invites each concerned authorization holder to present the necessary data and documents for the re-examination. For this purpose, it sets an appropriate deadline.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

If the risk of confusion between medicinal products or between medicinal products and other therapeutic products with a similar name or presentation is identified after a medicinal product has been placed on the market, Swissmedic shall order appropriate measures, including a change of name or graphic design.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

If an applicant submits an application for marketing authorization or for modification of an authorization for a medicinal product or process for which authorization has already been granted in a country with equivalent medicinal product control, Swissmedic shall take into account the results of the examination carried out for authorization, provided the following requirements are met: a. the submitted documents, derived from those used in the foreign procedure, including all modification notifications, are less than five years old and correspond to the status of foreign marketing authorization; b. the application is accompanied by the assessments performed abroad as part of the marketing authorization procedures, including the relevant examination results; c. the documents contain all data required for Switzerland, particularly regarding medicinal product information and labeling; d. the documents are available in an official language, in English, or have been translated into one of these languages; if a translation is necessary, the applicant confirms the accuracy of the translation.

The documents mentioned in para. 1, let. a, may differ slightly from the foreign documents, provided such modifications are duly justified. Another name for the medicinal product, a differently sized package, or another secondary packaging is notably considered a minor difference.

If a marketing authorization has been granted in an EU or EFTA member state, Swissmedic may approve, for the marketing of the medicinal product in Switzerland, the form of medicinal product information valid in the member state; Arts. 26 to 29 are reserved.

Swissmedic publishes a list of countries with equivalent medicinal product control.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic does not conduct its own scientific examination for the following applications: a. application for market approval of a process or medicinal product containing known active substances that has already been authorized in a country with equivalent drug control; b. application for market approval of a biosimilar that has already been authorized by the European Commission or the United States Food and Drug Administration.

It carries out a scientific examination: a. when the process or medicinal product has been subject to an authorization procedure in two or more countries with equivalent drug control and the decisions of the authorities in these states contradict each other; b. when the foreign authorization decision raises serious concerns in light of Swissmedic's previous examinations, new information published in specialized literature, or information obtained in the context of collaboration with other drug control authorities.

The scientific examination referred to in para. 2 is limited to doubtful points.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic conducts a comprehensive scientific examination of applications for marketing authorization of a medicinal product containing a new active substance, as well as applications concerning the extension of the indication of such a medicinal product. Based on the results of examinations carried out abroad, it may, upon request or on its own initiative, appropriately limit its examination in justified cases.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

When the application for marketing authorization concerns a medicinal product that has obtained a conditional marketing authorization in a country with an equivalent medicinal product control system, accompanied by specific conditions due to incomplete data on quality, safety, or efficacy, the result of the examination conducted by the foreign authority is only considered for granting a limited duration authorization according to Art. 9a of the Therapeutic Products Act (TPA).

All data subsequently provided and all results of examinations by the foreign authority relating to compliance with the specific conditions attached to the authorization must be submitted without delay to Swissmedic.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

If the European Medicines Agency (EMA) issues a recommendation to the European Commission or if a marketing authorization is granted in a country with an equivalent drug control system while a marketing authorization procedure is ongoing in Switzerland for the same drug or process, Swissmedic applies Articles 16 to 19 by analogy upon request. It continues its scientific assessment if, considering its previous reviews, there remain serious reservations regarding the results of the assessments conducted by the foreign authority.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The authorization holder is obliged to notify Swissmedic in writing of any minor modification whose impact on the quality, safety, or efficacy of the concerned medicinal product is minimal or negligible; for this purpose, they have a period of twelve months from the implementation of the modification.

Such modifications must be notified immediately in writing to Swissmedic upon implementation when necessary for the continuous monitoring of the medicinal product.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The authorization holder is required to notify Swissmedic in writing of any modification that does not constitute a modification referred to in Art. 21 or 23, nor an extension of the marketing authorization, before implementing the modification.

If Swissmedic raises no objection within 60 days following the receipt of a valid notification and complete documents, the modification is deemed accepted as of the day following the expiration of this period. If Swissmedic raises objections to the modification before the expiration of this period, the authorization holder has 30 days to provide the documents to resolve the objections or to submit a new notification duly addressing the objections. If the authorization holder fails to do so, the modification is deemed rejected.

Paragraph 2 does not apply when the notification of a modification according to paragraph 1 is submitted simultaneously with an application for approval of a major modification or an application for extension of the marketing authorization.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Modifications to a medicinal product that are likely to have significant impacts on its quality, safety, or efficacy and do not constitute an extension of the marketing authorization must be approved by Swissmedic before implementation.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Modifications to a medicinal product that are classified as an extension of the marketing authorization must undergo a new marketing authorization procedure.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic classifies each modification into one of the different categories and specifies the modalities of the procedures provided for in Art. 21 to 24, as well as the required documentation. In doing so, it takes into account internationally recognized standards and guidelines, notably Regulation (EC) No 1234/2008 and the guidelines of the European Commission based on this regulation.

It defines how an application may cover multiple modifications.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The authorization holder is required to notify Swissmedic in writing, after the implementation of the modification, of any modification that is not subject to evaluation because the impact on the quality, safety, or efficacy of the concerned medicinal product is minimal or negligible.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Modifications to a medicinal product that are submitted for evaluation due to their potential significant impact on the product's quality, safety, or efficacy must be approved by Swissmedic before they are implemented.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Swissmedic classifies each modification into one of the two categories and specifies the modalities of the procedures provided for in Art. 25a and 25b as well as the required documentation. In doing so, it takes into account internationally recognized standards and guidelines, notably Regulation (EU) 2019/6 and the implementing acts based on this regulation. It defines how a request may pertain to several modifications.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The texts and data appearing on the container and packaging material must be written in at least two official languages.

The information intended for professionals regarding medicinal products for human or veterinary use and their package inserts must be written in the three official languages.

The composition of the medicinal product may also be indicated in Latin or using standard international designations, such as the International Nonproprietary Names of the World Health Organization, on the container, packaging material, and in the information intended for professionals.

For medicines exclusively intended to be administered in hospitals and labeled accordingly, the indications referred to in paragraphs 1 and 2 may be written in one official language or in English. The authorization holder ensures that the user can receive additional information in the official language of their choice.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Medicinal products that are GMOs or contain GMOs must be designated as such.

The container intended for dispensing, the outer packaging, and the package leaflet must bear the statement "contains genetically modified X" or "produced from genetically modified X". The type of GMO and the genetic modification must be specified in the information intended for professionals.

The labeling of active substances and excipients obtained from GMOs is governed, by analogy, by the provisions concerning labeling set forth in the legislation on genetically modified foodstuffs.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The authorization holder is required to continuously and proactively adapt the drug information to the current state of scientific and technical knowledge, as well as to new events and evaluations. Articles 21 to 24, as well as 25a and 25b, apply.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The holder of the marketing authorization for a medicinal product for human or veterinary use is required to deliver to the institution referred to in Art. 67, para. 3, LPTh the content of the information on the medicinal product as prescribed by law, in the prescribed forms, no later than at the time of the first market release of the preparation.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The application for marketing authorization of a medicinal product that is very similar to an already authorized product and intended for the same use may refer to the results of pharmacological, toxicological, and clinical trials of the already authorized product provided that: a. the holder of the authorization for the already authorized product consents in writing, or b. the data exclusivity period has expired.

If a new indication, new method of administration, new pharmaceutical form, new dosage, new dosage recommendation, or application to a new animal species has been authorized for the already authorized product, the application referred to in para. 1 may refer to the results of the corresponding trials, provided that: a. the holder of the authorization for the already authorized product consents in writing, or b. the data exclusivity period granted for the modification of the authorization has expired.

Upon request, Swissmedic sets the data exclusivity referred to in para. 2, letter b, at ten years for a new indication if it can be expected to provide significant clinical benefit over existing therapies and is based on thorough clinical trials.

The data exclusivity referred to in Art. 11 b, para. 3, TPA is granted only if the studies submitted comply with the pediatric investigation plan referred to in Art. 54 a TPA.

Data exclusivity is granted with the marketing authorization and is published.

Swissmedic will not consider applications for authorization of a medicinal product referred to in Art. 12 TPA that are submitted more than two years before the expiration of the data exclusivity without the written consent of the holder of the authorization for the already authorized product.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Processes for the treatment of blood or labile blood products aimed at the inactivation or elimination of certain pathogens may only be marketed or used if they have been authorized by Swissmedic. Swissmedic grants authorization if the applicant demonstrates that the process inactivates or eliminates the pathogens and that the efficacy, safety, and quality of the product are not compromised. Any modification made to the process must be submitted for prior approval by Swissmedic.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Non-standardized transplants whose manufacturing process can be standardized may only be placed on the market or used for autologous transplantation if the process has been authorized by Swissmedic.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Non-standardized medicinal products whose manufacturing process can be standardized and which present a high risk due to their indication, composition, dosage, or method of administration, or because their safety and efficacy are not sufficiently supported by scientific publications, may only be marketed if their manufacturing process has been authorized by Swissmedic.

After consulting the cantons, Swissmedic designates the medicinal products or groups of medicinal products that require authorization pursuant to para. 1 and regularly updates this list based on the state of scientific and technical knowledge. It may accompany the updates to the list with transitional provisions.

If the list provided for in para. 2 no longer corresponds to current knowledge or developments and urgent measures are required to protect health, Swissmedic may provide the necessary instructions to the cantonal enforcement authorities, after prior consultation, pending the update of the list. These instructions are published on the Internet.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The provisions relating to the authorization for placing ready-to-use medicinal products on the market shall apply by analogy to the authorization of the processes referred to in Articles 31 to 33.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Medicinal products as defined in Art. 9, para. 2, let. b to c bis, LPTh may only be supplied to the clientele of the establishment.

By clientele of the establishment, it is meant the customers of a public pharmacy, a drugstore, or another establishment holding a cantonal authorization for retail trade, who acquire medicinal products for their own use or to administer them to third parties or animals.

In a hospital environment, in clinics, and in other medical establishments where pharmaceutical responsibility is entrusted to a single specialist, the clientele of the establishment consists of the following persons: a. inpatients within the establishment; b. outpatients who utilize the specific knowledge and equipment of the establishment.

Inpatients may receive an initial supply of medicinal products upon discharge from the establishment for their immediate needs.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The medicinal products referred to in Art. 9, para. 2, let. a to c bis, LPTh may only be manufactured or stocked in limited quantities per calendar year, corresponding to the usual needs of the establishment for one year, unless data relating to their stability justify a longer storage period.

Establishments tasked with custom manufacturing of medicinal products as defined in Art. 9, para. 2 bis, LPTh may only manufacture a medicinal product referred to in Art. 9, para. 2, let. a to c, LPTh in limited quantities per calendar year, up to a maximum of 3000 packages ready for distribution containing no more than 90,000 individual doses, per pharmaceutical form and per dosage. An establishment authorized to dispense medicinal products may only have the maximum quantities of the specified medicinal products custom-manufactured once per calendar year.

The restriction mentioned in para. 2 does not apply when no equivalent authorized substitute medicinal product is available in Switzerland or in a country with equivalent medicinal product regulation.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

Only those active substances that meet at least one of the following conditions may be used for the manufacture of medicinal products not requiring authorization as referred to in Art. 9, para. 2, let. a to c bis, 2 bis, and 2 ter of the Therapeutic Products Act (TPA): a. they are contained in a medicinal product authorized by Swissmedic or in a country that has established equivalent medicinal product control; b. they are listed in the list issued by Swissmedic concerning traditional Asian medicine and are used in compliance with the restrictions provided in this list; c. they are listed in the list issued by Swissmedic concerning homeopathic and anthroposophic medicine and are used in compliance with the restrictions provided in this list; d. they are mentioned in the Pharmacopoeia, or another pharmacopoeia or pharmaceutical formulary recognized by Swissmedic; e. they are used as a radiopharmaceutical product and are listed in Annex 1; f. they are used as an antidote or antivenom.

In justified exceptional cases, active substances not meeting the conditions mentioned in para. 1 may also be used for the manufacture of the medicinal products referred to in Art. 9, para. 2, let. a of the TPA, in compliance with recognized medical and pharmaceutical science rules: a. if they are not used as radiopharmaceutical products; b. if the medicinal product is intended for the diagnosis, prevention, or treatment of a serious disease that leads to disability or endangers the patient's life; c. if no substitute or equivalent medicinal product is available; d. if the intended use is expected to provide significant therapeutic benefit, and e. if a documented risk analysis justifies the intended use.

The cantons maintain and publish a list of the medicinal products referred to in para. 2, mentioning the active substances used and the relevant indications.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

For the manufacture of radiopharmaceutical products pursuant to Art. 9, para. 2, let. a to c bis, and 2 bis, LPTh, hospital radiopharmacy services are considered hospital pharmacies within the meaning of Art. 4, para. 1, let. j, LPTh.

OMéd; Chapitre 2 Procédure d’autorisation de mise sur le marché

The following information must appear on the containers and packages of medicinal products not subject to authorization as referred to in Art. 9, para. 2, lit. a to c bis, LPTh and intended to be supplied or used: a. medicinal products referred to in Art. 9, para. 2, lit. a, LPTh: "magistral formula"; b. medicinal products referred to in Art. 9, para. 2, lit. b, LPTh: "officinal formula"; c. medicinal products referred to in Art. 9, para. 2, lit. c, LPTh: "own formula"; d. medicinal products referred to in Art. 9, para. 2, lit. c bis, LPTh: "hospital formula".

Other texts and data as well as their formal aspects are governed by the Pharmacopoeia.

OMéd; Chapitre 3 Catégories de remise et remise

When granting market authorization, Swissmedic specifies the dispensing category of the medicinal product.

For classification into a dispensing category, it particularly considers the following aspects

a. pharmacological effect;

b. acute and chronic toxicity;

c. clinical experiences, particularly concerning safety and adverse effects;

d. field of application;

e. risk of misuse;

f. professional competencies that physicians and pharmacists must possess for safety reasons, in selecting and using the medicinal product.

It adjusts the classification, ex officio or upon request, based on the state of scientific and technical knowledge.

It publishes on its website the list of active substances contained in the medicinal products it has authorized. This list also specifies the dispensing category of the medicinal products.

Narcotics and psychotropic substances are subject to the specific provisions of the Ordinance of May 25, 2011, on Narcotics Control.

OMéd; Chapitre 3 Catégories de remise et remise

A medicinal product is classified in the category of drugs subject to non-renewable prescription without the express authorization of the physician (category A dispensing): a. if the duration of treatment is limited and, for safety reasons, cannot be extended without a medical or veterinary prescription; b. if its use without diagnosis or medical or veterinary supervision poses a risk of causing serious harm to health; c. if, due to erroneous use, the further treatment of serious conditions risks being decisively compromised.

OMéd; Chapitre 3 Catégories de remise et remise

A medicinal product is classified in the category of prescription-only medicines (dispensing category B) if: a. it is recommended for treating diseases that require a medical or veterinary diagnosis or supervision; b. it poses a direct or indirect health risk when used as intended without medical or veterinary diagnosis or supervision; c. it is frequently used in a manner not intended, which poses a direct or indirect health risk; d. it contains active substances or preparations of active substances whose effects and side effects need to be thoroughly studied; e. it is intended for administration via the parenteral route; f. its dispensing requires the advice of a person practicing a medical profession.

OMéd; Chapitre 3 Catégories de remise et remise

A medicinal product is classified in the category of dispensation with specialist advice (dispensation category D): a. if it does not fall into categories A or B, and b. if its dispensation or use requires specialist advice.

Medicinal products classified in this category can be dispensed without a medical or veterinary prescription by persons authorized under Art. 25, para. 1, let. a, b, and d, of the LPTh.

OMéd; Chapitre 3 Catégories de remise et remise

A medicinal product is classified in the category of over-the-counter medicines (dispensing category E): a. if it does not fall into categories A, B, or D, and b. if its dispensing or use does not require specialized advice.

Medicinal products classified in this category may be dispensed by anyone without a medical or veterinary prescription.

OMéd; Chapitre 3 Catégories de remise et remise

Pharmacists may dispense the following human medicinal products classified under dispensing category B without a prescription: a. medications used for treating common illnesses, as long as they contain well-known active substances that have been authorized for several years; b. medications used to continue long-term treatment for one year, following an initial medical prescription; c. medications whose dispensing requires, for safety reasons, advice from a person practicing in a medical profession, which belonged to dispensing category C until January 1, 2019, and have been reclassified by Swissmedic into category B; notably, these are medications that: 1. contain active substances with a well-known risk of abuse that may lead to habituation or dependence, 2. contain active substances that may have serious interactions with prescription medications, or 3. are subject to special documentation obligations.

The indications and authorized medications for these indications, as well as other conditions concerning dispensing as referred to in para. 1, let. a, are listed in annex 2.

The medications referred to in para. 1, let. c, are published on the Swissmedic website.

Systemic antibiotics cannot be dispensed according to para. 1.

OMéd; Chapitre 3 Catégories de remise et remise

Pharmacists may dispense the medicinal products referred to in Art. 4, let. b, of the Ordinance of 29 September 1995 on the Benefits of Health Insurance that have been prescribed by a chiropractor.

OMéd; Chapitre 3 Catégories de remise et remise

The dispensation pursuant to Art. 24, para. 1, let. a, nums. 1 and 2, LPTh can only be carried out by the pharmacist personally.

The patient for whom the medication is intended must be present in person for the evaluation and dispensation of the medication.

OMéd; Chapitre 3 Catégories de remise et remise

Any distribution pursuant to Art. 24, para. 1, let. a, items 1 and 2, LPTh must be recorded electronically or in writing.

The following information must be recorded: a. name, first name, date of birth, and gender of the patient; b. designation of the point of delivery and the person who carried out the delivery; c. name of the medication, dosage, and package size; d. date of delivery; e. information justifying the decision for delivery.

If the information is recorded in the electronic patient dossier in accordance with the Federal Act of June 19, 2015, on the Electronic Patient Dossier (EPD Act), the exchange formats provided for by the Federal Department of Home Affairs (FDHA) pursuant to Art. 10, para. 3, let. b, of the Ordinance of March 22, 2017, on the Electronic Patient Dossier (EPDO) must be complied with.

OMéd; Chapitre 3 Catégories de remise et remise

In addition to the persons referred to in Art. 25, para. 1, TPA, complementary medicine professionals holding a federal diploma are authorized to independently dispense, in the exercise of their profession, non-prescription medicines that Swissmedic has designated for this purpose.

OMéd; Chapitre 3 Catégories de remise et remise

The canton may authorize counselors from family planning services to dispense the "morning-after pill" in the course of their duties, provided they have received specific training recognized by the canton. The canton shall ensure that the dispensing procedure is reliable and uniform and that it is conducted under the direct supervision of a person practicing a medical profession.

OMéd; Chapitre 4 Exigences minimales applicables à la prescription d’un médicament à usage humain

The prescription from a physician or a chiropractor for a human medicinal product must contain at least the following information: a. the name, first name, and address of the medical practice of the person issuing the prescription along with their identification number listed in the medical professions register (GLN); b. legally valid signature of the person issuing the prescription; c. the name, first name, date of birth, and gender of the patient; d. the date the prescription is issued; e. the name of the preparation or the active ingredient, pharmaceutical form, if applicable, quantity of active ingredient per unit; f. dosage and duration of use; g. directions for use.

If the prescription is made on paper, it must bear the handwritten signature of the person issuing it. Electronic prescriptions may be equipped with a qualified electronic signature or transmitted in a manner that meets comparable security requirements in terms of authenticity, data integrity, and confidentiality.

Paragraphs 1 and 2 apply analogously to prescriptions by other healthcare professionals prescribing human medicinal products.

If the electronic prescription is recorded in the patient's electronic record as defined by the LDEP, the exchange formats established by the DFI pursuant to Art. 10, para. 3, let. b, ODEP must be adhered to.

OMéd; Chapitre 5 Administration de médicaments soumis à ordonnance

Any person intending to use prescription medicines in their professional practice and under their own responsibility must hold an authorization issued by the canton in which they practice their profession.

In addition to those practicing a medical profession, individuals from the following professional categories may obtain such authorization: a. holders of a Bachelor of Science in Midwifery (University of Applied Sciences); b. holders of a diploma in Dental Hygiene (Advanced Technical College); c. qualified chiropractors; d. holders of a diploma as a Paramedic (Advanced Technical College); e. persons referred to in Art. 49; f. holders of a Bachelor of Science in Optometry (University of Applied Sciences).

The canton specifies which medicines may be administered by the persons referred to in para. 2.

It ensures that regular supervision is provided by the cantonal authority or an appropriate person practicing a medical profession.

OMéd; Chapitre 5 Administration de médicaments soumis à ordonnance

The canton may authorize dentists with cantonal authorization to use prescription drugs that are necessary for the practice of their profession.

OMéd; Chapitre 6 Restrictions à la distribution

The holder of the authorization may distribute immunological veterinary medicinal products, with the exception of allergens, only to veterinarians or competent authorities.

OMéd; Chapitre 7 Autorisation de vente par correspondance de médicaments

Anyone applying for a mail-order authorization for pharmaceuticals must hold a cantonal authorization that allows them to operate a public pharmacy.

Furthermore, the applicant must, using a quality assurance system, ensure that: a. the recipient of the medication is indeed the person for whom the medical prescription was written; b. the medical prescription has been verified to prevent any adverse interaction with other medications provided to the recipient; c. the packaging, transportation, and delivery of the medication are appropriate to guarantee its quality and effectiveness; d. the medication is delivered in its original packaging with the package insert and specific instructions for use; e. the sent medication is delivered only to the person for whom the medical prescription was written or to a third party in possession of a written power of attorney from said person; f. the patient has been informed that they must contact their treating physician if any issues arise in connection with the sent medication; and g. advice has been provided according to best practices by a healthcare professional.

The requirements concerning the prescription, dispensing, and use of veterinary medicines must be complied with in accordance with the Ordinance of August 18, 2004, on Veterinary Medicines.

OMéd; Chapitre 7 Autorisation de vente par correspondance de médicaments

The cantons shall maintain a joint list of pharmacies that have a mail-order sales license.

OMéd; Chapitre 8 Surveillance du marché

The subsequent control of the lawfulness of the distribution and use of medicinal products placed on the market falls within the competence of the cantons.

The cantons control, by sampling or upon request from Swissmedic, if the distribution points comply notably with

a. the regulations concerning distribution rights;

b. the regulations concerning advertising for medicinal products;

c. the requirements concerning the labeling of medicinal products.

If, after control, it appears that the provisions specified in para. 2, let. a, have been violated, the canton carries out the necessary investigations and orders the required measures. It informs Swissmedic.

If, after control, it appears that the provisions specified in para. 2, let. b and c, or other provisions of the Therapeutic Products Act or the present ordinance have been violated, the canton reports to Swissmedic. Swissmedic carries out the necessary investigations and orders the required measures. It informs the cantons.

OMéd; Chapitre 8 Surveillance du marché

The supervision of the legality of the distribution of authorized or license-required medicinal products and labile blood products falls under the jurisdiction of Swissmedic. It checks in particular: a. whether the medicinal products requiring market authorization possess a valid authorization issued by it; b. whether the conditions and requirements imposed by it are being complied with.

Furthermore, it regularly verifies, pursuant to Art. 58, para. 2, of the Therapeutic Products Act (LPTh), whether the authorized medicinal products comply with the market authorization, particularly with regard to: a. composition; b. specifications; c. quality requirements; d. medicinal product information; e. packaging material.

It may require the necessary documents within the framework of these checks.

If, after verification, it appears that any provisions of the LPTh or this ordinance have been violated, it prescribes the necessary measures.

OMéd; Chapitre 8 Surveillance du marché

Swissmedic may conduct product-focused inspections at any time if it deems necessary.

Inspections abroad and the assignments of inspectors are governed by Art. 60, paras. 2 and 3, and 62 OAMed.

OMéd; Chapitre 8 Surveillance du marché

The holder of an authorization for a medicinal product containing a new active substance or containing a biosimilar must submit to Swissmedic, periodically and voluntarily during the four years following the granting of the authorization, an updated report on the safety and benefit-risk profile of the medicinal product.

For veterinary medicinal products, the updated report referred to in para. 1 may be submitted in the form of an annual report presenting the results and conclusions of the benefit-risk assessment, as well as references to relevant scientific literature, which are recorded in the European Union's pharmacovigilance database as part of the signal management process.

The reports must be prepared in accordance with the recognized good vigilance practices designated in Annex 3.

OMéd; Chapitre 8 Surveillance du marché

The manufacturer or the authorization holder must report to Swissmedic any serious adverse effects and previously unknown effects observed in Switzerland, which are presumed to be related to the use of their medicinal product.

The manufacturer or the authorization holder must also report to Swissmedic when the adverse effects mentioned in para. 1 become frequent.

The reports provided for in paras. 1 and 2 must be communicated in an anonymized form, include all important data available, and particularly mention whether the adverse effect of the medicinal product is known.

The manufacturer or the authorization holder must report to Swissmedic the adverse effects, observed in Switzerland or abroad, which are presumed to be related to the use of their medicinal product: a. when it concerns a previously unknown risk or a new aspect of a known risk that requires study or the implementation of measures to reduce the risk or has led to taking measures to reduce the risk abroad, or b. when such adverse effects become frequent.

The information related to the risks referred to in para. 4 (safety signals) must be summarized and evaluated in a report. This report is communicated to Swissmedic along with the planned measures and investigations.

The manufacturer or the authorization holder must report to Swissmedic: a. quality defects observed in Switzerland; b. quality defects observed abroad that may concern batches marketed in Switzerland.

For labile blood products, the reporting of quality defects is governed by Art. 37 OMed.

OMéd; Chapitre 8 Surveillance du marché

The following adverse effects must be reported within the respective periods after being discovered: a. 15 days: 1. any serious adverse effect, 2. any known or previously unknown adverse effect that becomes frequent; b. 60 days: any minor adverse effect that was previously unknown.

Safety signals must be reported after observation: a. immediately and no later than within five days for safety signals that rapidly require measures to ensure medicinal product safety; b. within 15 days for other safety signals involving a potentially serious risk.

Quality defects identified in Switzerland or abroad as per Art. 61, para. 6, must be reported to Swissmedic immediately and no later than 15 days following the discovery.

OMéd; Chapitre 8 Surveillance du marché

Anyone who manufactures or places medicinal products on the market is obliged to report to Swissmedic without delay, but no later than within five days, any suspicion of illegal trafficking committed by third parties, which is related to their activity, one of their products, or a component thereof.

OMéd; Chapitre 8 Surveillance du marché

Persons who distribute or use medicinal products professionally or who are authorized to do so are required to report: a. any suspected serious adverse effect related to the use of a medicinal product; b. any previously unknown suspected adverse effect; c. any suspected quality defect; d. any observation of serious or previously unknown facts compromising the safety of medicinal products.

These reports must be communicated to the services designated by Swissmedic; they must include all important available data.

Serious adverse effects and serious observed facts must be reported within 15 days. Suspected quality defects must be reported immediately and no later than 15 days after detection. All other events to be reported must be communicated within 60 days.

OMéd; Chapitre 8 Surveillance du marché

The obligation to report events and adverse effects related to the use of a medicinal product, as well as quality defects, commences at the time of filing the application for marketing authorization and expires upon the expiration date of the last batch delivered.

OMéd; Chapitre 8 Surveillance du marché

Anyone who manufactures or distributes ready-to-use medicinal products must ensure that all information subject to the reporting obligation is collected by a central body hosted by the authorization holder or the manufacturer. This information must be continually evaluated, and all measures to mitigate potential risks must be implemented.

The body referred to in para. 1 must ensure that the information to be reported is transmitted to Swissmedic in accordance with the applicable provisions. It must provide Swissmedic with complete responses regarding the risks associated with the use of the relevant medicinal products within the deadlines set by Swissmedic.

The authorization holder or the manufacturer shall designate a qualified technical official responsible for fulfilling the obligation to report adverse drug effects. This task may be delegated to a qualified third party. The requirements that this person must meet are defined in Art. 12, para. 1, lit. d, and para. 2, OAMed.

Establishments using labile blood products shall establish a quality assurance system for this purpose in accordance with the current state of scientific and technical knowledge. They must designate a responsible officer to fulfill the reporting obligation.

OMéd; Chapitre 8 Surveillance du marché

The content of the declarations provided for in Articles 61 to 65 must comply with the recognized good vigilance practices designated in Annex 3.

Swissmedic provides the forms.

OMéd; Chapitre 9 Principes des bonnes pratiques de laboratoire

The applicant must ensure that the trial programs, the conduct of the various trials, the methods applied, and the evaluation of the results correspond to the current state of scientific and technical knowledge.

Non-clinical trials intended to establish the properties or safety of the tested object must be conducted in accordance with the principles of good laboratory practice pursuant to the ordinance of 18 May 2005 on good laboratory practice.

The provisions of para. 2 do not apply to efficacy trials.

If the applicant cannot comply with all or part of the requirements referred to in para. 2 for certain trials, they must justify it to Swissmedic. In duly justified cases, Swissmedic will evaluate the quality and reliability of the trial and verify whether the requirements referred to in para. 1 are met; it will decide whether to consider the corresponding non-clinical trials.

OMéd; Chapitre 10 Information

Swissmedic publishes: a. within 60 days following the receipt of a complete application for marketing authorization, extension of indication, or extension of marketing authorization for a medicinal product: 1. the name and address of the applicant, 2. the date the application was submitted, 3. the active ingredients contained in the medicinal product, 4. the intended scope of application, 5. the animal species concerned; b. when an application for marketing authorization, extension of indication, or extension of authorization for a medicinal product is approved, or when a marketing authorization is revoked and the related decision has been notified, notably: 1. the name and address of the authorization holder or the applicant, 2. the name of the medicinal product, 3. the active ingredients, 4. the scope of application, 5. the animal species concerned, 6. the date of the decision; c. when an application as referred to in letter b is rejected or withdrawn and the related decision has been notified, the information mentioned in letter b, points 1 and 3 to 6; d. the duration of data exclusivity granted pursuant to Articles 11a and 11b of the Therapeutic Products Act (TPA); e. summary reports, concerning notably: 1. the acceptance or rejection of marketing authorization applications for human-use medicinal products containing new active ingredients or applications for extension of indication for such medicinal products, 2. risk management plans; f. results of market surveillance of interest for the safety of medicinal products; g. information on market surveillance measures, especially when they include action recommendations or result in a modification of the marketing authorization.

It is incumbent upon the applicant to assert, in their application, interests worthy of protection for maintaining secrecy that could oppose the publication of the data referred to in para. 1, letter a.

The publications referred to in para. 1 are made in the language of the procedure. They may be made in English if the scientific documents upon which they are based are written in this language.

OMéd; Chapitre 10 Information

Persons practicing a medical profession who work in pediatric hospitals in Switzerland shall transmit to the Federal Office of Public Health (FOPH) the data specified in the annex concerning the off-label dosage of medicinal products used in pediatrics. The data must align with the current state of scientific and technical knowledge, as well as the rules of medical and pharmaceutical sciences. Based on this data, the FOPH issues harmonized national recommendations for off-label dosages.

OMéd; Chapitre 10 Information

The harmonized Off Label dosage recommendations are made available to professionals and federal and cantonal authorities responsible for the implementation of the Therapeutic Products Act (LPTh) in the form of a list published online in an interoperable format. Consultation of these recommendations is free of charge.

The recommendations may be reused in hospital information systems or similar systems. These systems must ensure that when consulting the data, the source of the recommendations is indicated.

OMéd; Chapitre 10 Information

The holder of the marketing authorization for a medicinal product for human use containing a new active substance is required to publish the results of the clinical trials conducted for the development of the medicinal product in the form of a report within three months following the granting of the authorization.

If the authority granting marketing authorizations in a country with equivalent drug control has already published a report on the results of the clinical trials, the authorization holder may refer to this publication.

OMéd; Chapitre 10 Information

The reports on the results of clinical trials must contain at least the information listed in Annex 5.

They may be published in one of the official languages or in English.

OMéd; Chapitre 10 Information

Reports on the results of clinical trials must be anonymized.

The authorization holder may exclude data related to trade secrets or commercial secrets from publication.

OMéd; Chapitre 11 Traitement des données

Swissmedic and third parties mandated by it are authorized to process the personal data necessary for fulfilling the tasks assigned to them by the present ordinance. This includes, in particular: a. health data collected in the context of market surveillance; b. data certifying that the individuals responsible for fulfilling the obligation to report adverse drug reactions under Art. 65, para. 3, are trustworthy and possess the required qualifications.

OMéd; Chapitre 11 Traitement des données

Swissmedic is responsible for the security of the operation of its information systems and for the legality of data processing.

It issues regulations for each information system applicable to data processing. These regulations specify the technical and organizational measures to be implemented to ensure the security and protection of processed data.

If it delegates tasks in the field of vigilance to third parties, it ensures data protection compliance through contractual arrangements.

OMéd; Chapitre 11 Traitement des données

Online access to information systems is granted to the following services and individuals, if necessary for the fulfillment of their duties: a. members of Swissmedic staff working in the field of vigilance and market monitoring, as well as third parties mandated to perform tasks in this area; b. members of Swissmedic staff working in the field of administrative criminal law; c. Swissmedic administrators and mandated third parties.

All accesses to the information systems are recorded in logs (logging). The logging logs are retained for two years, separately from the system in which personal data is processed.

OMéd; Chapitre 11 Traitement des données

Data concerning an individual are retained: a. for ten years from the last entry; b. for twenty years from the last entry if it was based on a criminal judgment or a final decision by Swissmedic regarding the exercise of an activity without having obtained the required authorization from Swissmedic.

Personal data contained in Swissmedic's information systems are destroyed upon the expiration of the marketing authorization for the medicinal product concerned by the declarations and the archiving of the authorization dossier.

OMéd; Chapitre 12 Dispositions finales

Swissmedic may specify the technical requirements and modalities necessary for the implementation of this ordinance.

OMéd; Chapitre 12 Dispositions finales

The Federal Department of Home Affairs (FDHA) may adapt the annexes of this ordinance in accordance with international or technical developments.

Any adaptations that may create technical barriers to trade are made in agreement with the Federal Department of Economic Affairs, Education and Research.

Annex 1 is updated after consultation with the Radiopharmaceuticals Commission, in accordance with Art. 32 of the Ordinance of 22 June 1994 on Radiological Protection.

The FDHA may seek assistance from experts to adapt Annex 2.

OMéd; Chapitre 12 Dispositions finales

Prior to the first authorization of an active substance for a veterinary medicinal product, the agreement of the Federal Office for the Environment (FOEN) must be obtained. For the execution of other provisions, the FOEN is consulted in cases of particular impact on the environment or upon its request.

Before the first use of an active substance for a medicinal product intended for human use, an environmental risk assessment must be conducted. The assessment is carried out according to the EMA guideline of 1 June 2006 for the environmental risk assessment of medicinal products for human use. The FOEN is consulted in cases of particular impact on the environment or upon its request.

For the execution of provisions concerning medicinal products containing GMOs, collaboration is governed by the Ordinance of 10 September 2008 on the Deliberate Release into the Environment.

OMéd; Chapitre 12 Dispositions finales

Swissmedic shall, upon request, communicate to the FOPH: a. data on the risks associated with vaccines; b. data relating to medicinal products, insofar as they are necessary for the implementation of the Federal Act of 18 March 1994 on Health Insurance and its implementing provisions.

The data referred to in para. 1 must not contain sensitive data.

OMéd; Chapitre 12 Dispositions finales

The repeal and amendment of other acts are regulated in Annex 6.

OMéd; Chapitre 12 Dispositions finales

If a pediatric investigation plan concerning a medicinal product for which a marketing authorization was requested before 1 January 2019 is submitted for approval to Swissmedic, the obligation to present the pediatric investigation plan provided for in Art. 5, para. 2, let. c, applies to all subsequent modifications of the medicinal product.

OMéd; Chapitre 12 Dispositions finales

Marketing authorizations for medicinal products issued prior to the entry into force of Art. 16b LPTh must be renewed at least once after January 1, 2019.

OMéd; Chapitre 12 Dispositions finales

The data exclusivity provided for in Art. 11b TPA is granted only for medicinal products for which a marketing authorization application or a modification of the authorization is submitted to Swissmedic after January 1, 2019.

OMéd; Chapitre 12 Dispositions finales

The manufacturing processes for non-standardized medicinal products, which did not require authorization until January 1, 2019, and now require one under Art. 33, para. 1, must be subject to an authorization application within one year from the publication of the list referred to in Art. 33, para. 2.

Medicinal products manufactured according to the process outlined in para. 1 may remain on the market until Swissmedic reaches a decision, unless Swissmedic decides otherwise for safety reasons.

OMéd; Chapitre 12 Dispositions finales

Professionals authorized to dispense medicinal products of Dispensing Category C retain their authorization under the former law until the new classification into dispensing categories comes into force for the relevant medicinal products.

Pharmacists granted the authorization by the cantons to dispense medicinal products of Dispensing Category C under the former law retain their authorization or may have it renewed until the new classification into dispensing categories comes into force for all relevant medicinal products.

Swissmedic informs the cantons of the completion of the reclassification procedure.

OMéd; Chapitre 12 Dispositions finales

Pharmacists without a federal diploma who, as of 1 January 2019, were authorized to dispense category D medicinal products pursuant to Art. 44c of the Ordinance of 17 October 2001 on Medicinal Products, may continue to dispense these medicinal products until 1 January 2024.

OMéd; Chapitre 12 Dispositions finales

This ordinance enters into force on 1 January 2019, subject to paragraph 2.

Articles 37, paragraphs 2 and 3, and 51 enter into force on 1 January 2020.

Need to analyze how this provision applies to your matter?

Cross-reference this statute against case law, commentaries, and related legislative provisions inside Legislator AI.

Open in Legislator →